Insight Molecular Diagnostics Inc. IMDX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Insight Molecular Diagnostics Inc. reported revenue across 3 products and services; the largest, Laboratory Services, was $4.03M, 99.4% of the filed sum (+116.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Laboratory Services$4.03M99.4%+116.8% yoy
- Kitted Products$24K0.6%no prior
- Laboratory Developed Test Services$00.0%-100.0% yoy
Members sum to the consolidated $4.05M for this period.
- United States$4.03M99.4%+140.9% yoy
- Europe$24K0.6%+33.3% yoy
- Asia Pacific$00.0%-100.0% yoy
- United Kingdom$00.0%-100.0% yoy
Members sum to the consolidated $4.05M for this period.
- Laboratory Services$32K100.0%-98.5% yoy
- Kitted Products$00.0%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.